Ocaliva
Intercept Pharmaceuticals, After 2 FDA Setbacks and Restructuring Efforts, Finds a Buyer in Italy’s Alfasigma
Anika Sharma
Intercept Pharmaceuticals has faced substantial challenges over the past three years, particularly after the FDA rejected its attempts to bring ...
Intercept Implements Restructuring as Ocaliva’s Hopes for NASH Treatment Suffer Another FDA Rejection
SG Tylor
Source – Intercept Ocaliva by Intercept wasn’t the fatty liver disease breakthrough that the company had anticipated it would be, ...
